Evaluating the cancer therapeutic potential of cardiac glycosides

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Calderón Montaño, José Manuel ^a   Burgos Morón, Estefanía ^a   Orta, Manuel Luis ^a   Maldonado Navas, Dolores ^a   García Domínguez, Irene ^a   López Lázaro, Miguel ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARENOBUFAGIN; BUFALIN; BUFOTALIN; CARDIAC GLYCOSIDE; DIGITOXIN; DIGOXIN; LANATOSIDE C; OUABAIN; PERIPLOCIN; UNBS 1450; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; DRUG SCREENING; EXPERIMENTAL STUDY; HUMAN; NONHUMAN; REVIEW; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIAC GLYCOSIDES; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS;

EID: 84901796521     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/794930     Document Type: Review

References (55)

1. Rahimtoola S. H., Tak T., The use of digitalis in heart failure. Current Problems in Cardiology 1996 21 12 781 853
2. Xie Z., Askari A., Na+/K+-ATPase as a signal transducer. European Journal of Biochemistry 2002 269 10 2434 2439 2-s2.0-0036098774 10.1046/j.1432-1033. 2002.02910.x (Pubitemid 34539270)
3. Schoner W., Scheiner-Bobis G., Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. American Journal of Physiology-Cell Physiology 2007 293 2 C509 C536 2-s2.0-34547733409 10.1152/ajpcell.00098.2007 (Pubitemid 47235171)
4. Haux J., Digitoxin is a potential anticancer agent for several types of cancer. Medical Hypotheses 1999 53 6 543 548 2-s2.0-0033383637 10.1054/mehy.1999.0985 (Pubitemid 30064132)
5. López-Lázaro M., Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opinion on Therapeutic Targets 2007 11 8 1043 1053 2-s2.0-34547754022 10.1517/14728222.11. 8.1043 (Pubitemid 47232620)
6. Newman R. A., Yang P., Pawlus A. D., Block K. I., Cardiac glycosides as novel cancer therapeutic agents. Molecular Interventions 2008 8 1 36 49 2-s2.0-40849124038 10.1124/mi.8.1.8 (Pubitemid 351398451)
7. Prassas I., Diamandis E. P., Novel therapeutic applications of cardiac glycosides. Nature Reviews Drug Discovery 2008 7 11 926 935 2-s2.0-55349103358 10.1038/nrd2682
8. Mijatovic T., Van Quaquebeke E., Delest B., Debeir O., Darro F., Kiss R., Cardiotonic steroids on the road to anti-cancer therapy. Biochimica et Biophysica Acta-Reviews on Cancer 2007 1776 1 32 57 2-s2.0-34548306962 10.1016/j.bbcan.2007.06.002 (Pubitemid 47334788)
9. +-ATPase to combat chemoresistant cancers. Current Medicinal Chemistry 2012 19 5 627 646 2-s2.0-84857709614 10.2174/092986712798992075
10. +-ATPase targeting could circumvent various chemoresistance pathways. Planta Medica 2013 79 3-4 189 198 10.1055/s-0032- 1328243
11. Slingerland M., Cerella C., Guchelaar H. J., Diederich M., Gelderblom H., Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials. Invest New Drugs 2013 31 4 1087 1094
12. +-ATPase and cardiac glycosides to cytotoxicity and cancer treatment. Anti-Cancer Agents in Medicinal Chemistry 2013 13 7 1069 1087
13. Cerella C., Dicato M., Diederich M., Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosides. Mitochondrion 2013 13 3 225 234
14. Sreenivasan Y., Raghavendra P. B., Manna S. K., Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. Journal of Clinical Immunology 2006 26 4 308 322 2-s2.0-33745913613 10.1007/s10875-006-9028-0 (Pubitemid 44051378)
15. Hallböök H., Felth J., Eriksson A., Fryknäs M., Bohlin L., Larsson R., Gullbo J., Ex vivo activity of cardiac glycosides in acute leukaemia. PLoS ONE 2011 6 1 2-s2.0-79251584614 10.1371/journal.pone.0015718 e15718
16. López-Lázaro M., Pastor N., Azrak S. S., Ayuso M. J., Austin C. A., Cortés F., Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. Journal of Natural Products 2005 68 11 1642 1645 2-s2.0-29044433675 10.1021/np050226l (Pubitemid 41789573)
17. Zhang H., Qian D. Z., Tan Y. S., Lee K., Gao P., Ren Y. R., Rey S., Hammers H., Chang D., Pili R., Dang C. V., Liu J. O., Semenza G. L., Digoxin and other cardiac glycosides inhibit HIF-1 α synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America 2008 105 50 19579 19586 2-s2.0-58149374576 10.1073/pnas.0809763105
18. Tailler M., Senovilla L., Lainey E., Thepot S., Metivier D., Sebert M., Baud V., Billot K., Fenaux P., Galluzzi L., Boehrer S., Kroemer G., Kepp O., Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene 2012 31 30 3536 3546
19. Wang Y., Lonard D. M., Yu Y., Chow D. C., Palzkill T. G., Wang J., Qi R., Matzuk A. J., Song X., Madoux F., Hodder P., Chase P., Griffin P. R., Zhou S., Liao L., Xu J., O'Malley B. W., Bufalin is a potent small molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Research 2014 74 5 1506 1517
20. Rashan L. J., Franke K., Khine M. M., Kelter G., Fiebig H. H., Neumann J., Wessjohann L. A., Characterization of the anticancer properties of monoglycosidic cardenolides isolated from Nerium oleander and Streptocaulon tomentosum. Journal of Ethnopharmacology 2011 134 3 781 788 2-s2.0-79954422260 10.1016/j.jep.2011.01.038
21. Calderon-Montano J. M., Burgos-Moron E., Orta M. L., Mateos S., Lopez-Lazaro M., A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells. Planta Medica 2013 79 12 1017 1023 10.1055/s-0032-1328715
22. Perne A., Muellner M. K., Steinrueck M., Craig-Mueller N., Mayerhofer J., Schwarzinger I., Sloane M., Uras I. Z., Hoermann G., Nijman S. M. B., Mayerhofer M., Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PloS ONE 2009 4 12 e8292 2-s2.0-77949524121
23. Clifford R. J., Kaplan J. H., Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS ONE 2013 8 12 e84306
24. Calderon-Montano J. M., Burgos-Moron E., Lopez-Lazaro M., The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact. Oncogene 2013 10.1038/onc.2013.229
25. Lopez-Lazaro M., Digoxin, HIF-1, and cancer. Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 E26 2-s2.0-62549094806 10.1073/pnas.0813047106
26. Calderon-Montano J. M., Burgos-Moron E., Lopez-Lazaro M., Comment on "Quiescence and gammaH2AX in neuroblastoma are regulated by Ouabain/Na, K-ATPase": ouabain and cancer. British Journal of Cancer 2013 108 10 2189 2190
27. Hiyoshi H., Abdelhady S., Segerstrom L., Sveinbjornsson B., Nuriya M., Lundgren T. K., Desfrere L., Miyakawa A., Yasui M., Kogner P., Johnsen J. I., Andang M., Uhlen P., Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na, K-ATPase. British Journal of Cancer 2012 106 11 1807 1815
28. Zhang D. M., Liu J. S., Deng L. J., Chen M. F., Yiu A., Cao H. H., Tian H. Y., Fung K. P., Kurihara H., Pan J. X., Ye W. C., Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis 2013 34 6 1331 1342
29. Gupta R. S., Chopra A., Stetsko D. K., Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis). Journal of Cellular Physiology 1986 127 2 197 206 2-s2.0-0022521980 (Pubitemid 16074723)
30. Mijatovic T., Roland I., Van Quaquebeke E., Nilsson B., Mathieu A., Van Vynckt F., Darro F., Blanco G., Facchini V., Kiss R., The α 1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. Journal of Pathology 2007 212 2 170 179 2-s2.0-34249825771 10.1002/path.2172 (Pubitemid 46852095)
31. Yang P., Menter D. G., Cartwright C., Chan D., Dixon S., Suraokar M., Mendoza G., Llansa N., Newman R. A., Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase α subunits as drug targets. Molecular Cancer Therapeutics 2009 8 8 2319 2328 2-s2.0-68849107545 10.1158/1535-7163.MCT-08-1085
32. + -ATPase alpha subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog 2012
33. Svensson A., Azarbayjani F., Bäckman U., Matsumoto T., Christofferson R., Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Research 2005 25 1 207 212 2-s2.0-16344369879 (Pubitemid 40470112)
34. Zavareh R. B., Lau K. S., Hurren R., Datti A., Ashline D. J., Gronda M., Cheung P., Simpson C. D., Liu W., Wasylishen A. R., Boutros P. C., Shi H., Vengopal A., Jurisica I., Penn L. Z., Reinhold V. N., Ezzat S., Wrana J., Rose D. R., Schachter H., Dennis J. W., Schimmer A. D., Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Research 2008 68 16 6688 6697 2-s2.0-53049106681 10.1158/0008-5472.CAN-07-6833
35. Wong C. C., Zhang H., Gilkes D. M., Chen J., Wei H., Chaturvedi P., Hubbi M. E., Semenza G. L., Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. Journal of Molecular Medicine 2012 90 7 803 815
36. Zhang H., Wong C. C. L., Wei H., Gilkes D. M., Korangath P., Chaturvedi P., Schito L., Chen J., Krishnamachary B., Winnard P. T. Jr., Raman V., Zhen L., Mitzner W. A., Sukumar S., Semenza G. L., HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012 31 14 1757 1770 2-s2.0-84860389759 10.1038/onc.2011.365
37. Schito L., Rey S., Tafani M., Zhang H., Wong C. C., Russo A., Russo M. A., Semenza G. L., Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2012 109 40 E2707 E2716
38. Gayed B. A., 'Malley K. J. O., Pilch J., Wang Z., Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors. Clinical and Translational Science 2012 5 1 39 42
39. Antczak C., Kloepping C., Radu C., Genski T., Müller-Kuhrt L., Siems K., de Stanchina E., Abramson D. H., Djaballah H., Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo antitumor activity of cardenolides. Investigative Ophthalmology and Visual Science 2009 50 7 3065 3073 2-s2.0-67649992705 10.1167/iovs.08-3158
40. Simpson C. D., Mawji I. A., Anyiwe K., Williams M. A., Wang X., Venugopal A. L., Gronda M., Hurren R., Cheng S., Serra S., Zavareh R. B., Datti A., Wrana J. L., Ezzat S., Schimmer A. D., Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Research 2009 69 7 2739 2747 2-s2.0-66149142810 10.1158/0008-5472.CAN-08-2530
41. Mijatovic T., De Beeck A. O., Van Quaquebeke E., Dewelle J., Darro F., de Launoit Y., Kiss R., The cardenolide UNBS1450 is able to deactivate nuclear factor B-mediated cytoprotective effects in human non-small cell lung cancer cells. Molecular Cancer Therapeutics 2006 5 2 391 399 2-s2.0-33644974357 10.1158/1535-7163.MCT-05-0367
42. Mijatovic T., Mathieu V., Gaussin J., De Nève N., Ribaucour F., Van Quaquebeke E., Dumont P., Darro F., Kiss R., Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006 8 5 402 412 2-s2.0-33744824903 10.1593/neo.05850 (Pubitemid 43830747)
43. Mijatovic T., De Nève N., Gailly P., Mathieu V., Haibe-Kains B., Bontempi G., Lapeira J., Decaestecker C., Facchini V., Kiss R., Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Molecular Cancer Therapeutics 2008 7 5 1285 1296 2-s2.0-49849100632 10.1158/1535-7163.MCT- 07-2241
44. Lefranc F., Mijatovic T., Kondo Y., Sauvage S., Roland I., Debeir O., Krstic D., Vasic V., Gailly P., Kondo S., Blanco G., Kiss R., Targeting the α 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008 62 1 211 221 2-s2.0-41749099092 10.1227/01.NEU.0000311080.43024.0E
45. Mathieu V., Pirker C., Martin de Lassalle E., Vernier M., Mijatovic T., DeNeve N., Gaussin J., Dehoux M., Lefranc F., Berger W., Kiss R., The sodium pump α 1 sub-unit: a disease progression-related target for metastatic melanoma treatment. Journal of Cellular and Molecular Medicine 2009 13 9 3960 3972 2-s2.0-70350080771 10.1111/j.1582-4934.2009.00708.x
46. Lu Z. J., Zhou Y., Song Q., Qin Z., Zhang H., Zhou Y. J., Gou L. T., Yang J. L., Luo F., Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. Cellular Physiology and Biochemistry 2010 26 4-5 609 618 2-s2.0-78149461619 10.1159/000322328
47. Cheng C. F., Lu I. H., Tseng H. W., Sun C. Y., Lin L. T., Kuo Z. K., Pan I. H., Ko C. H., Antitumor effect of periplocin in TRAIL-resistant human hepatocellular carcinoma cells through downregulation of IAPs. Evidence-Based Complementary and Alternative Medicine 2013 2013 11 958025 10.1155/2013/958025
48. Badr C. E., Wurdinger T., Nilsson J., Niers J. M., Whalen M., Degterev A., Tannous B. A., Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosisinducing ligand and induces an alternative cell death pathway. Neuro-Oncology 2011 13 11 1213 1224 2-s2.0-80755125542 10.1093/neuonc/nor067
49. Chen Y., Guo Q., Zhang B., Kang M., Xie Q., Wu Y., Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncology Letters 2012 4 4 792 798
50. Xie X. B., Yin J. Q., Wen L. L., Gao Z. H., Zou C. Y., Wang J., Huang G., Tang Q. L., Colombo C., He W. L., Jia Q., Shen J. N., Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS ONE 2012 7 10 e47375
51. Zhang D. M., Liu J. S., Tang M. K., Yiu A., Cao H. H., Jiang L., Chan J. Y., Tian H. Y., Fung K. P., Ye W. C., Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. European Journal of Pharmacology 2012 692 1-3 19 28
52. Han N., Yang J., Li L., Xiao B., Sha S., Tran L., Yin J., Wu C., Inhibitory activity of a phytochemically characterized fraction from streptocaulon juventas on lung cancer in nude mice. Planta Medica 2010 76 6 561 565 2-s2.0-77951031281 10.1055/s-0029-1240600
53. Takai N., Ueda T., Nishida M., Nasu K., Narahara H., Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. International Journal of Molecular Medicine 2008 21 5 637 643 2-s2.0-46449105600
54. Moreno Y. B., Urban E., Gelbcke M., Dufrasne F., Kopp B., Kiss R., Zehl M., Structure-activity relationship analysis of bufadienolide-induced in vitro growth inhibitory effects on mouse and human cancer cells. Journal of Natural Products 2013 76 6 1078 1084
55. Elbaz H. A., Stueckle T. A., Wang H. L., O'Doherty G. A., Lowry D. T., Sargent L. M., Wang L., Dinu C. Z., Rojanasakul Y., Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells. Toxicology and Applied Pharmacology 2012 258 1 51 60 2-s2.0-84855431152 10.1016/j.taap.2011.10.007